Novartis and Novo Nordisk Heart Drug Trials Fail
Two major cardiovascular trials failed to reach their primary end points in recent results released by pharma leaders.
Updated on Oct. 16, 2026 in Heart Disease
Live Poll
Should you prioritize proven lifestyle changes over experimental treatments for managing your long-term cardiovascular health?
On July 31 and September 4, 2026, Novo Nordisk and Novartis respectively reported that their phase 3 cardiovascular clinical trials failed to meet primary end points. Both studies were intended to demonstrate reduced major adverse cardiovascular events in high-risk patient populations.
Why it matters
The failure of these late-stage trials represents a setback in developing targeted therapies for patients with established cardiovascular disease and underlying comorbidities. These results highlight the challenges of achieving statistically significant clinical improvements in complex patient groups.
The Lp(a)HORIZON trial enrolled 8,323 patients, while the ZEUS study evaluated over 6,300 participants. Patients in the ZEUS arm received 15 mg of monthly subcutaneous ziltivekimab.
The players
Novartis
Novartis is a multinational pharmaceutical corporation based in Switzerland that focuses on the research and development of innovative medicines.
Novo Nordisk
Novo Nordisk is a Danish pharmaceutical company known for its global leadership in diabetes care and advancements in metabolic disease treatments.
The details
In the ZEUS trial, researchers found that ziltivekimab, a monoclonal antibody targeting the IL-6 ligand, did not reduce major adverse cardiovascular events compared to a placebo. Meanwhile, the Lp(a)HORIZON study showed that while pelacarsen successfully lowered lipoprotein(a) levels, it failed to meet its primary composite end point among patients with cardiovascular disease.
Timeline
July 31, 2026: Novo Nordisk reported ZEUS trial results.
September 4, 2026: Novartis announced Lp(a)HORIZON trial results.
The Big Picture
These results follow a pattern set by established cardiovascular outcomes trial benchmarks for proving clinical efficacy in large-scale patient populations. Failure to meet these standards sets a high bar for future therapies seeking regulatory approval for risk reduction.
Patients currently managing cardiovascular disease through standard of care should continue their prescribed routines as these experimental treatments did not demonstrate a clinical benefit. These results may influence future clinical trial participation criteria and treatment strategies for heart disease patients.
The takeaway
Clinical drug development remains highly unpredictable despite promising early-stage biomarkers for lipid reduction. Patients should consult their cardiologists regarding established treatments rather than relying on experimental therapeutic outcomes.
What happens next
Full data from the Lp(a)HORIZON trial will be presented at an upcoming medical congress.
Further reading
For broader context on current research, visit our Heart Disease section.
More information
Review the full Novartis phase 3 trial results for more information.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Should you prioritize proven lifestyle changes over experimental treatments for managing your long-term cardiovascular health?
